Ultragenyx Pharmaceutical Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Ultragenyx Pharmaceutical Inc 公司

Ultragenyx Pharmaceutical Inc. 是一家生物製藥公司。該公司專注於識別、收購、開發和商業化用於治療嚴重罕見和極罕見遺傳病的新產品。其療法和臨牀階段產品線包括四類產品：生物製劑、小分子、AAV 基因治療和核酸候選產品。該公司的四種獲批候選產品包括用於治療 X 連鎖低磷血癥 (XLH) 和腫瘤誘發性骨軟化症 (TIO) 的 Crysvita (burosumab)、用於治療粘多糖貯積症 VII (MPSVII) 或 Sly 綜合徵的 Mepsevii (vestronidase alfa)、用於治療長鏈脂肪酸氧化障礙 (LC-FAOD) 的 Dojorvi (triheptanoin) 和用於治療純閤家族性高膽固醇血癥 (HoFH) 的 Evkeeza (evinacumab)。其臨牀候選產品包括DTX401、DTX301和UX701。DTX401用於治療Ia型糖原累積病。

公司簡介

公司代碼RARE

公司名稱Ultragenyx Pharmaceutical Inc

上市日期Jan 31, 2014

成立日期2011

CEODr. Emil D. Kakkis, M.D., Ph.D.

員工數量1294

證券類型Ordinary Share

年結日Jan 31

公司地址60 Leveroni Ct

城市NOVATO

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編94949

電話14154838800

網址https://www.ultragenyx.com/

公司代碼RARE

上市日期Jan 31, 2014

成立日期2011

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.69M

-1.17%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

107.20K

+41.78%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

41.99K

+83.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

27.34K

+26.57%

Mr. Michael A. Narachi

Independent Director

27.34K

+26.57%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.59K

+38.64%

Dr. Amrit Ray, M.D.

Independent Director

18.02K

+46.74%

Mr. Howard Horn

Chief Financial Officer, Executive Vice President, Corporate Strategy

15.69K

-83.00%

Mr. John R. Pinion, II

Chief Quality Officer, Executive Vice President - Translational Sciences

--

Dr. Deborah L. Dunsire, M.D.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.69M

-1.17%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

107.20K

+41.78%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

41.99K

+83.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

27.34K

+26.57%

Mr. Michael A. Narachi

Independent Director

27.34K

+26.57%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.59K

+38.64%

收入明細

單位: USD更新時間: 7月6日週日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

業務USD

名稱

營收

佔比

Crysvita

55.08M

39.54%

Crysvita royalty revenue

47.78M

34.31%

Dojolvi

17.01M

12.21%

Evkeeza

11.03M

7.92%

Mepsevii

8.39M

6.02%

地區USD

名稱

營收

佔比

North America

57.79M

41.49%

Latin America

54.89M

39.40%

Europe

23.33M

16.75%

Japan

3.29M

2.36%

業務

地區

業務USD

名稱

營收

佔比

Crysvita

55.08M

39.54%

Crysvita royalty revenue

47.78M

34.31%

Dojolvi

17.01M

12.21%

Evkeeza

11.03M

7.92%

Mepsevii

8.39M

6.02%

股東統計

更新時間: 5月17日週六

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

10.55%

BlackRock Institutional Trust Company, N.A.

5.20%

Sands Capital Management, LLC

4.40%

T. Rowe Price Associates, Inc.

3.32%

Kakkis (Emil D)

2.85%

Other

73.68%

持股股東

佔比

The Vanguard Group, Inc.

10.55%

BlackRock Institutional Trust Company, N.A.

5.20%

Sands Capital Management, LLC

4.40%

T. Rowe Price Associates, Inc.

3.32%

Kakkis (Emil D)

2.85%

Other

73.68%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

44.96%

Investment Advisor

27.79%

Hedge Fund

21.16%

Individual Investor

3.56%

Research Firm

1.72%

Sovereign Wealth Fund

1.02%

Private Equity

0.70%

Pension Fund

0.65%

Bank and Trust

0.28%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

627

96.81M

102.40%

-2.03M

2025Q1

652

96.83M

102.45%

-3.19M

2024Q4

645

94.29M

102.32%

-4.54M

2024Q3

633

93.51M

101.49%

-6.93M

2024Q2

618

95.17M

101.90%

+3.05M

2024Q1

605

86.17M

101.67%

-4.74M

2023Q4

588

86.44M

105.27%

+5.64M

2023Q3

574

75.90M

106.07%

-3.60M

2023Q2

591

75.05M

105.07%

-3.13M

2023Q1

609

74.12M

105.56%

-2.85M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

9.98M

10.55%

-38.64K

-0.39%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.91M

5.2%

-49.62K

-1.00%

Mar 31, 2025

Sands Capital Management, LLC

4.16M

4.4%

-134.44K

-3.13%

Mar 31, 2025

T. Rowe Price Associates, Inc.

3.14M

3.32%

+698.80K

+28.65%

Mar 31, 2025

Kakkis (Emil D)

2.69M

2.85%

-31.78K

-1.17%

Mar 07, 2025

State Street Global Advisors (US)

2.62M

2.77%

-104.13K

-3.82%

Mar 31, 2025

Wellington Management Company, LLP

2.45M

2.59%

-8.04K

-0.33%

Mar 31, 2025

ClearBridge Investments, LLC

2.26M

2.39%

-62.50K

-2.69%

Mar 31, 2025

Adage Capital Management, L.P.

2.15M

2.27%

+965.92K

+81.64%

Mar 31, 2025

Federated Hermes Global Investment Management Corp.

2.05M

2.17%

+3.00K

+0.15%

Mar 31, 2025

持股ETF

更新時間: 7月6日週日

機構名稱

佔比

Global X Genomics & Biotechnology ETF

3.89%

Motley Fool Small-Cap Growth ETF

3%

Motley Fool Mid-Cap Growth ETF

2.01%

Franklin Genomic Advancements ETF

2%

Virtus LifeSci Biotech Products ETF

1.84%

Touchstone Sands Capital US Select Growth ETF

1.26%

WisdomTree BioRevolution Fund

1.12%

SPDR S&P Biotech ETF

0.77%

Putnam Sustainable Future ETF

0.63%

Goldman Sachs Future Health Care Equity ETF

0.6%

Global X Genomics & Biotechnology ETF

佔比3.89%

Motley Fool Small-Cap Growth ETF

佔比3%

Motley Fool Mid-Cap Growth ETF

佔比2.01%

Franklin Genomic Advancements ETF

佔比2%

Virtus LifeSci Biotech Products ETF

佔比1.84%

Touchstone Sands Capital US Select Growth ETF

佔比1.26%

WisdomTree BioRevolution Fund

佔比1.12%

SPDR S&P Biotech ETF

佔比0.77%

Putnam Sustainable Future ETF

佔比0.63%

Goldman Sachs Future Health Care Equity ETF

佔比0.6%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Ultragenyx Pharmaceutical Inc

31.035USD

Ultragenyx Pharmaceutical Inc

31.035

概覽

公司

財務